VAMP5 (Vesicle-Associated Membrane Protein 5), also known as myeloblast-associated homolog, is a member of the VAMP/synaptobrevin family of SNARE proteins critical for intracellular membrane fusion and vesicle trafficking. Unlike its well-studied homologs VAMP1/2 (involved in neuronal and regulated secretion), VAMP5 is classified as a non-neuronal R-SNARE with a distinct localization pattern. It is highly expressed in tissues such as skeletal muscle, lung, and endothelial cells, where it facilitates the fusion of secretory vesicles with the plasma membrane. VAMP5 contains a conserved SNARE motif but lacks the canonical transmembrane domain, instead anchoring to membranes via a cysteine-rich region.
VAMP5 antibodies are essential tools for investigating its role in cellular processes like exocytosis, endocytosis, and pathogen entry mechanisms. Studies suggest VAMP5 participates in glucose transporter GLUT4 translocation in muscle cells, implicating it in metabolic disorders like diabetes. It also interacts with SNARE partners like SNAP23 and syntaxin-4 to mediate inflammatory cytokine release in endothelial dysfunction, linking it to cardiovascular pathologies. Commercially available antibodies (monoclonal/polyoclonal) are validated for applications including Western blotting, immunofluorescence, and co-immunoprecipitation, often using knockout cell lines as specificity controls. Recent research highlights VAMP5's potential as a therapeutic target in hypertension, atherosclerosis, and bacterial/viral infections that hijack vesicle pathways. However, its functional overlap with other VAMPs and tissue-specific regulation remain active areas of investigation.